Favipiravir, A Novel Anti-Influenza Virus Compound Inhibits Viral RNA Polymerase: Effects on QT Prolongation.
Phase of Trial: Phase I
Latest Information Update: 01 Oct 2015
At a glance
- Drugs Favipiravir (Primary) ; Moxifloxacin
- Indications Bacterial infections; Influenza virus infections
- Focus Adverse reactions
- 21 Sep 2011 New trial record
- 17 Sep 2011 Results presented at the 51st Interscience Conference on Antimicrobial Agents and Chemotherapy.